Prof. Tilman Sauerbruch: patients with HCC may be benefit from statins
HBSN: Do you and your team have any research being conducted? Are there any interesting findings?
Prof. Sauerbruch: I've been interested in the treatment and pathophysiology of portal hypertension for many years. We are looking for new drugs and new treatments for portal hypertension and the possibility to treat portal hypertension with statins. We also look for modulation of signaling pathways within the myofibroblast or the hepatic stellate cells. In addition, we are evaluating the effect of small TIPS (transjugular intrahepatic portosystemic shunt) lumen as compared to large diameter TIPS. Furthermore we evaluate the effect of nonselective β-blockers on portal hypertension with respect to hemodynamic response and prophylaxis of bleeding from esophageal varices.
6
2019-07-18(万方平台首次上网日期,不代表论文的发表时间)
共2页
365-366